Press Releases
Apr. 24, 2014 biOasis Discovers the Keys to Transcend to Advance its Program for the Delivery of Therapeutics Across the Blood-Brain Barrier
This Represents A Major Finding For the Company, Its Partners, Potential Partners and Shareholders
Apr. 3, 2014 biOasis Presents Results From Its BT2111 Program at International Cancer Research Conference
biOasis and collaborators from Alexandria University, Egypt; Texas Tech University HSC, Amarillo, Texas and; the West Virginia University HSC, School of Pharmacy, Morgantown, WV; Presents Progress in Developing a Novel Therapy to Treat Brain Metastases of Breast Cancer
Mar. 27, 2014 biOasis Receives Patent Allowances for Lysosomal Storage Disease Therapeutic in Europe and Canada
Key Patent Allowances Represent Major Step Toward International Exclusivity for its LSD- Therapeutic in the $2 Billion LSD Market
Mar. 17, 2014 biOasis Enters into a License Agreement with MedImmune for Second Generation Versions of biOasis’s Transcend
Vancouver, British Columbia–(Business Wire)– biOasis Technologies, Inc. (OTCQX:BIOAF; TSXV:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, has signed an evaluation agreement with MedImmune, the global biologics research and development arm of AstraZeneca. Under the terms of the agreement, MedImmune will evaluate the therapeutic effect of… Read more »
Feb. 24, 2014 biOasis to Begin Trading on OTCQX® Marketplace in the U.S.
Vancouver, British Columbia–(Business Wire)– biOasis Technologies Inc. (OTCQX:BIOAF) (TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, has up listed on the highest tier of the off- market, OTCQX® under the symbol BIOAF. “Joining the OTCQX brings greater visibility and awareness of biOasis to the US… Read more »
Dec. 4, 2013 Option Grant – biOasis Technologies Inc.
Vancouver, British Columbia–(Business Wire)– biOasis Technologies Inc. (TSX: V BTI) (the “Company”) announces that, pursuant to the terms of its Stock Option Plan, the company has granted a total of 1,700,000 options to its officers, employees, consultants and members of the board of directors. 1,550,000 of the options are exercisable at a price of $0.97… Read more »
Nov. 13, 2013 Study Demonstrates biOasis Technologies’ Conjugate of Metastatic Cancer Drug, Herceptin, Penetrates Blood-tumor Barrier 10 Times Greater than Herceptin Alone
Vancouver, British Columbia–(Business Wire)– biOasis Technologies Inc. (TSXV:BTI) (OTCBB: BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, reported that new research conducted under its BT2111 (Herceptin®) program shows that BT2111-a conjugate of the metastatic cancer drug, Herceptin® not only crosses the blood-brain barrier, but also… Read more »
Oct. 18, 2013 biOasis Presents Research Results on BT2111 (Transcend-Trastuzumab) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Vancouver, British Columbia–(Business Wire)– biOasis Technologies Inc. (TSX:V BTI) is pleased to announce that preclinical data on its proprietary BT2111 program will be presented during the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held in Boston, MA from October 19-23, 2013. biOasis’ presentation entitled “BT2111, a new anticancer agent composed of trastuzumab… Read more »
Oct. 2, 2013 biOasis Engages Liolios Group to Lead New Investor Relations Program
Vancouver, British Columbia–(Business Wire)– biOasis Technologies, Inc. (TSX.V: BTI, OTCBB: BIOAF), a pioneer in the delivery of therapeutics across the blood-brand barrier, has engaged Liolios Group to lead a new investor relations and financial communications campaign. “Over the course of the last 12 months, leading independent researchers have demonstrated how our Transcend™ technology is able… Read more »
Sep. 5, 2013 biOasis to Present at the 2013 Gateway Conference on September 10
Vancouver, British Columbia–(Business Wire)– biOasis Technologies, Inc. (TSX-V: BTI, OCTQX:BIOAF), a biopharmaceutical company focused on the delivery of therapeutics across the blood-brain barrier to treat a host of brain diseases and disorders, has been invited to present at the 2013 Gateway Conference being held on Tuesday, September 10, 2013 at the Palace Hotel in San… Read more »